TransMedics Group Inc (TMDX)

Currency in USD
107.29
-5.69(-5.04%)
Closed·
106.50-0.79(-0.74%)
·
TMDX Scorecard
Full Analysis
Net income is expected to grow this year
TMDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
107.22114.00
52 wk Range
55.00145.50
Key Statistics
Prev. Close
112.98
Open
113.54
Day's Range
107.22-114
52 wk Range
55-145.5
Volume
987.15K
Average Volume (3m)
1.09M
1-Year Change
-17.64%
Book Value / Share
9.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TMDX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
140.67
Upside
+31.11%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

TransMedics Group Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

TransMedics Group Inc Company Profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group Inc SWOT Analysis


Organ Tech Pionee
TransMedics leads organ transplant innovation with its Organ Care System, revolutionizing preservation and transport of donor organs
Financial Health
Strong revenue growth and ambitious targets highlight TransMedics' potential, with 2024 guidance projecting up to 79% year-over-year increase
Market Expansion
TransMedics aims for 10,000 transplants by 2028, targeting $1.2 billion in revenue through new product lines and international growth
Analyst Outlook
Price targets range from $90 to $110, reflecting confidence in TransMedics' growth potential despite recent CFO transition and market challenges
Read full SWOT analysis

TransMedics Group Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.92 beat expectations by 104.44%, revenue up 38% YoY to $157.4M
  • Stock rose 3.13% post-announcement, with 1.55% gain in aftermarket trading
  • Full-year revenue guidance raised to $585-$605M, targeting 35% YoY increase
  • U.S. transplant revenue grew 40% YoY; company aims for 30% operating margin by 2028
  • Exploring European market expansion; confident in heart and lung clinical trials growth
Last Updated: 31/07/2025, 00:02
Read Full Transcript

Compare TMDX to Peers and Sector

Metrics to compare
TMDX
Peers
Sector
Relationship
P/E Ratio
51.0x23.7x−0.7x
PEG Ratio
0.02−2.220.00
Price/Book
11.5x1.9x2.6x
Price / LTM Sales
6.9x8.2x3.4x
Upside (Analyst Target)
35.1%0.0%38.0%
Fair Value Upside
Unlock11.2%5.3%Unlock

Analyst Ratings

7 Buy
4 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 140.67
(+31.11% Upside)

Earnings

Latest Release
Jul 30, 2025
EPS / Forecast
0.92 / 0.45
Revenue / Forecast
157.40M / 146.74M
EPS Revisions
Last 90 days

TMDX Income Statement

People Also Watch

206.12
ALAB
-8.57%
18.77
OSCR
-8.62%
64.250
RKLB
-3.27%
82.019
ASTS
-5.50%
13.8200
EOSE
-5.60%

FAQ

What Stock Exchange Does TransMedics Trade On?

TransMedics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for TransMedics?

The stock symbol for TransMedics is "TMDX."

What Is the TransMedics Market Cap?

As of today, TransMedics market cap is 3.85B.

What Is TransMedics's Earnings Per Share (TTM)?

The TransMedics EPS (TTM) is 2.02.

When Is the Next TransMedics Earnings Date?

TransMedics will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is TMDX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has TransMedics Stock Split?

TransMedics has split 0 times.

How Many Employees Does TransMedics Have?

TransMedics has 728 employees.

What is the current trading status of TransMedics (TMDX)?

As of 10 Oct 2025, TransMedics (TMDX) is trading at a price of 107.29, with a previous close of 112.98. The stock has fluctuated within a day range of 107.22 to 114.00, while its 52-week range spans from 55.00 to 145.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.